未满足的需求和新兴的药物疗法,用于自身免疫结缔组织疾病相关的间歇性肺部疾病
Yasuhiro Kondoh1, Takao Fujii2, Yoshikazu Inoue3
1Department of Respiratory Medicine and Allergology, Aichi Medical University, Nagakute, Japan.
Autoimmunity reviews
|August 6, 2025
概括
需要新的药物用于结合组织疾病相关的间歇性肺病 (CTD-ILD) 和渐进性肺纤维化 (PPF). 像内兰多米拉斯特这样的有希望的候选药物在这些渐进的肺部疾病中提供了潜在的抗纤维和免疫调节益处.
科学领域:
- 肺部病理学 肺部病理学
- 类风湿病学 类风湿病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 连接组织疾病相关的间歇性肺病 (CTD-ILD) 包括诸如类风湿性关节炎-ILD和全身性硬化症-ILD等疾病.
- 许多CTD-ILD患者和其他患有间歇性肺病 (ILD) 的患者会发展成渐进性肺纤维化 (PPF),反映异常性肺纤维化 (IPF),症状恶化和结果不佳.
- 目前对CTD-ILD和PPF的治疗方法,包括葡萄糖皮质类药物,免疫抑制剂和抗纤维素药物,具有有限的疗效和显著的副作用,突出显示了未满足的医疗需求.
研究的目的:
- 审查目前CTD-ILD和PPF药物治疗的现状.
- 识别和讨论目前正在临床试验中的有前途的新型治疗药物,用于这些渐进性纤维化肺部疾病.
- 强调需要更有效和更耐受的治疗方法来减轻CTD-ILD和PPF的负担.
主要方法:
- 对CTD-ILD和PPF的现有和新兴药物疗法的文献综述.
- 对针对纤维化和炎症途径的新型化合物的临床试验数据的分析.
- 对研究药物的潜在作用机制和临床前发现进行讨论.
主要成果:
- 现有的CTD-ILD和PPF治疗方法,如宁泰达尼布,主要减缓疾病进展,并具有治疗限制的副作用.
- 几种有前途的候选药物正在临床开发中,包括内兰多米拉斯 (一种PDE4B抑制剂),阿德米尔帕兰特 (一种LPAR1抗剂) 和吸入式特雷普罗斯尼尔 (一种前环素类似物).
- 尼兰多米拉斯通过减少炎症细胞和亲纤维细胞信号传递,显示出临床前的抗纤维和免疫调节作用.
结论:
- 对于CTD-ILD和PPF而言,急需新的,更有效和更耐受的药物疗法.
- 实验药物如内兰多米拉斯特,阿德米尔帕兰特和吸入式特雷普罗斯尼尔代表着解决这些进展性肺部疾病的重大负担的有希望的管道.
- 这些药物的进一步临床开发可能会改善CTD-ILD和PPF患者的治疗结果和生活质量.
相关概念视频
Drugs Used in Lower Respiratory Disorders: Overview
583
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
583
Inflammatory Bowel Disease IV: Pharmacological Management
190
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
190
Antiasthma Drugs: Leukotriene Modifiers
475
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
475
Autoimmune Disorders
676
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
676
Connective Tissue Cell Types
3.4K
Connective tissue develops from the mesoderm of a developing embryo and consists of cells, fibers, and ground substance: a gel-like material containing large complexes of carbohydrates and proteins. Connective tissue was first identified as a separate tissue family in the 18th century, and Johannes Peter Muller coined the term connective tissue.
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
Fat cells (adipocytes), smooth muscle cells (myoblasts), and bone cells (osteoblasts) are some connective tissue cell types. Some immune system cells...
3.4K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
254
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
254


